Please login to the form below

Not currently logged in
Email:
Password:

Biogen Idec appoints new CEO

Biogen Idec has appointed George A Scangos, a veteran of Elelixis and Bayer, as the company's new CEO and a member of the board of directors

Biogen Idec has appointed George A Scangos, a veteran of Elelixis and Bayer, as the company's new CEO and a member of the board of directors, effective July 15. He succeeds James C Mullen, who is retiring after 20 years at the company.

Scangos joins Biogen Idec from the cancer drug development company Exelixis, where he has been president and CEO since 1996. Earlier, he spent a decade at Bayer, beginning with the company as a staff scientist, then becoming senior vice president of Research and Development, and finally advancing to the post of president of Bayer Biotechnology, where he had responsibility for research, business development, process development, manufacturing, engineering, and quality assurance of biological products.

He holds a PhD in microbiology and began his career as a professor at Johns Hopkins University.

Biogen Idec has three marketed products: the multiple sclerosis drugs Avonex (interferon beta-1a) and Tysabri (natalizumab), and Rituxan (rituximab), which is approved for non-Hodgkin's lymphoma and rheumatoid arthritis. The company's pipeline includes more than 20 products in late-stage clinical development.

Scangos said his priorities as he begins his tenure will be to advance the firm's marketed products while preparing for the potential launch of five new products over a three-year period. He said he will also focus on forging new partnerships for the company and hiring a new head of R&D.

1st July 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics